ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has announced its plans to report financial results for Q2 2024 on August 14, 2024, after the U.S. financial markets close. The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results, provide updates on recent corporate developments, and answer questions.
Participants are encouraged to pre-register for the call using a provided link, which will grant them immediate access with a unique PIN. Those unable to pre-register can dial in using specific U.S. and International numbers. A webcast of the call will be accessible through ENDRA's Investor Relations page. Both telephone and webcast replays will be available until August 21, 2024.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), pioniere della Thermo Acoustic Enhanced UltraSound (TAEUS®), ha annunciato i suoi piani per riportare i risultati finanziari per il Q2 2024 il 14 agosto 2024, dopo la chiusura dei mercati finanziari statunitensi. L'azienda ospiterà una chiamata in conferenza e una trasmissione in diretta alle 16:30 ora orientale per discutere i risultati, fornire aggiornamenti su recenti sviluppi aziendali e rispondere alle domande.
Si incoraggiano i partecipanti a pre-registrarsi per la chiamata utilizzando un link fornito, che garantirà loro accesso immediato con un PIN unico. Coloro che non possono pre-registrarsi possono chiamare utilizzando numeri specifici degli Stati Uniti e internazionali. Una trasmissione in diretta della chiamata sarà accessibile attraverso la pagina delle Relazioni con gli Investitori di ENDRA. Sia le registrazioni telefoniche che quelle della trasmissione in diretta saranno disponibili fino al 21 agosto 2024.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), pionero de la Thermo Acoustic Enhanced UltraSound (TAEUS®), ha anunciado sus planes para reportar resultados financieros del Q2 2024 el 14 de agosto de 2024, después del cierre de los mercados financieros estadounidenses. La compañía llevará a cabo una llamada de conferencia y una transmisión en vivo a las 4:30 p.m. hora del Este para discutir los resultados, proporcionar actualizaciones sobre desarrollos corporativos recientes y responder preguntas.
Se alienta a los participantes a pre-registrarse para la llamada utilizando un enlace proporcionado, que les dará acceso inmediato con un PIN único. Aquellos que no puedan pre-registrarse pueden marcar utilizando números específicos de EE.UU. e internacionales. Una transmisión en vivo de la llamada estará accesible a través de la página de Relaciones con Inversores de ENDRA. Tanto las repeticiones por teléfono como la transmisión en vivo estarán disponibles hasta el 21 de agosto de 2024.
ENDRA 생명과학 주식회사 (NASDAQ: NDRA), Thermo Acoustic Enhanced UltraSound (TAEUS®)의 선도 기업, 2024년 2분기 재무 결과를 2024년 8월 14일, 미국 주식 시장 폐장 후에 보고할 예정이라고 발표했습니다. 이 회사는 결과를 논의하고 최근 기업 개발에 대한 업데이트를 제공하며 질문에 답하기 위해 동부 표준시 기준 오후 4시 30분에 회의 전화 및 웹캐스트를 진행할 것입니다.
참가자들은 제공된 링크를 사용하여 사전 등록을 할 것을 권장합니다. 이 링크를 통해 고유한 PIN으로 즉시 접속할 수 있습니다. 사전 등록하지 못한 분들은 특정 미국 및 국제 번호로 전화하실 수 있습니다. 회의의 웹캐스트는 ENDRA의 투자자 관계 페이지를 통해 이용할 수 있습니다. 전화 및 웹캐스트 재생은 2024년 8월 21일까지 가능합니다.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), pionnier de la Thermo Acoustic Enhanced UltraSound (TAEUS®), a annoncé ses plans pour communiquer les résultats financiers du T2 2024 le 14 août 2024, après la clôture des marchés financiers américains. L'entreprise organisera une conférence téléphonique et un webinaire à 16h30 heure de l'Est pour discuter des résultats, fournir des mises à jour sur les développements récents de l'entreprise et répondre aux questions.
Les participants sont encouragés à se pré-enregistrer pour l'appel en utilisant un lien fourni, ce qui leur donnera un accès immédiat avec un code PIN unique. Ceux qui ne peuvent pas se pré-enregistrer peuvent composer des numéros spécifiques aux États-Unis et internationaux. Un webinaire de l'appel sera accessible via la page des relations investisseurs d'ENDRA. Les rediffusions téléphoniques et web seront disponibles jusqu'au 21 août 2024.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), Pionier der Thermo Acoustic Enhanced UltraSound (TAEUS®), hat angekündigt, die Finanzergebnisse für das 2. Quartal 2024 am 14. August 2024 nach dem Handelsschluss der US-Finanzmärkte zu veröffentlichen. Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz und eine Webübertragung abhalten, um die Ergebnisse zu besprechen, aktuelle Unternehmensentwicklungen zu präsentieren und Fragen zu beantworten.
Die Teilnehmer werden ermutigt, sich über einen bereitgestellten Link vorab zu registrieren, was ihnen sofortigen Zugang mit einer einzigartigen PIN ermöglicht. Wer sich nicht vorab registrieren kann, kann sich über bestimmte US- und internationalen Nummern einwählen. Eine Webübertragung der Konferenz wird über die Investorenrelationsseite von ENDRA verfügbar sein. Sowohl Telefon- als auch Webübertragungswiederholungen sind bis zum 21. August 2024 verfügbar.
- None.
- None.
Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the start of the call. Those unable to pre-register may participate by dialing (844) 868-8846 (
A telephone replay will be available until August 21, 2024 by dialing (877) 344-7529 (
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/40th the cost and at the point of patient care. TAEUS® is designed to work in concert with the more than 700,000 ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD) (formerly known as NAFLD-NASH), a chronic liver spectrum that affects over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807031500/en/
Company Contact:
Irina Pestrikova
Senior Director, Finance
investors@endrainc.com
www.endrainc.com
Investor Relations Contact:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
ybriggs@lhai.com
Source: ENDRA Life Sciences Inc.
FAQ
When will ENDRA Life Sciences (NDRA) report its Q2 2024 financial results?
How can investors participate in ENDRA's (NDRA) Q2 2024 earnings call?
Will there be a replay available for ENDRA's (NDRA) Q2 2024 earnings call?
What is ENDRA Life Sciences' (NDRA) main technology focus?
